Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study

Annalisa Mondi; Massimiliano Fabbiani; Nicoletta Ciccarelli; Manuela Colafigli; Alessandro D'Avino; Alberto Borghetti; Roberta Gagliardini; Roberto Cauda; Andrea De Luca; Simona Di Giambenedetto

doi:10.1093/jac/dkv037

Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study

Annalisa Mondi, Massimiliano Fabbiani^*, Nicoletta Ciccarelli, Manuela Colafigli, Alessandro D'Avino, Alberto Borghetti, Roberta Gagliardini, Roberto Cauda, Andrea De Luca, Simona Di Giambenedetto

^*Autore corrispondente per questo lavoro

Risultato della ricerca: Contributo in rivista › Articolo

31 Citazioni (Scopus)

Abstract

AtLaS was a single-arm pilot study that demonstrated promising efficacy and safety of treatment simplification to a dual regimen with atazanavir/ritonavir + lamivudine in virologically suppressed HIV-positive patients. Here, we report data from the 144 week follow-up.

Lingua originale	Inglese
pagine (da-a)	1843-1849
Numero di pagine	7
Rivista	Journal of Antimicrobial Chemotherapy
Volume	70
Numero di pubblicazione	6
DOI	https://doi.org/10.1093/jac/dkv037
Stato di pubblicazione	Pubblicato - 2015

All Science Journal Classification (ASJC) codes

Farmacologia
Microbiologia (medica)
Malattie Infettive
Farmacologia (medica)

Keywords

antiviral
combined antiretroviral therapy
dual therapy

OSS delle Nazioni Unite

Questo processo contribuisce al raggiungimento dei seguenti obiettivi di sviluppo sostenibile

Accesso al documento

10.1093/jac/dkv037

Altri file e collegamenti

Cita questo

Mondi, A., Fabbiani, M., Ciccarelli, N., Colafigli, M., D'Avino, A., Borghetti, A., Gagliardini, R., Cauda, R., De Luca, A., & Di Giambenedetto, S. (2015). Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study. Journal of Antimicrobial Chemotherapy, 70(6), 1843-1849. https://doi.org/10.1093/jac/dkv037

@article{8f8baea8f34d4f77b38a417660cf48c1,

title = "Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study",

abstract = "AtLaS was a single-arm pilot study that demonstrated promising efficacy and safety of treatment simplification to a dual regimen with atazanavir/ritonavir + lamivudine in virologically suppressed HIV-positive patients. Here, we report data from the 144 week follow-up.",

keywords = "antiviral, combined antiretroviral therapy, dual therapy, antiviral, combined antiretroviral therapy, dual therapy",

author = "Annalisa Mondi and Massimiliano Fabbiani and Nicoletta Ciccarelli and Manuela Colafigli and Alessandro D'Avino and Alberto Borghetti and Roberta Gagliardini and Roberto Cauda and \{De Luca\}, Andrea and \{Di Giambenedetto\}, Simona",

year = "2015",

doi = "10.1093/jac/dkv037",

language = "English",

volume = "70",

pages = "1843--1849",

journal = "Journal of Antimicrobial Chemotherapy",

issn = "0305-7453",

publisher = "Oxford University Press",

number = "6",

}

Mondi, A, Fabbiani, M, Ciccarelli, N, Colafigli, M, D'Avino, A, Borghetti, A, Gagliardini, R, Cauda, R, De Luca, A & Di Giambenedetto, S 2015, 'Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study', Journal of Antimicrobial Chemotherapy, vol. 70, n. 6, pagg. 1843-1849. https://doi.org/10.1093/jac/dkv037

Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study. / Mondi, Annalisa; Fabbiani, Massimiliano; Ciccarelli, Nicoletta et al.
In: Journal of Antimicrobial Chemotherapy, Vol. 70, N. 6, 2015, pag. 1843-1849.

Risultato della ricerca: Contributo in rivista › Articolo

TY - JOUR

T1 - Efficacy and safety of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients with virological suppression: 144 week follow-up of the AtLaS pilot study

AU - Mondi, Annalisa

AU - Fabbiani, Massimiliano

AU - Ciccarelli, Nicoletta

AU - Colafigli, Manuela

AU - D'Avino, Alessandro

AU - Borghetti, Alberto

AU - Gagliardini, Roberta

AU - Cauda, Roberto

AU - De Luca, Andrea

AU - Di Giambenedetto, Simona

PY - 2015

Y1 - 2015

N2 - AtLaS was a single-arm pilot study that demonstrated promising efficacy and safety of treatment simplification to a dual regimen with atazanavir/ritonavir + lamivudine in virologically suppressed HIV-positive patients. Here, we report data from the 144 week follow-up.

AB - AtLaS was a single-arm pilot study that demonstrated promising efficacy and safety of treatment simplification to a dual regimen with atazanavir/ritonavir + lamivudine in virologically suppressed HIV-positive patients. Here, we report data from the 144 week follow-up.

KW - antiviral

KW - combined antiretroviral therapy

KW - dual therapy

KW - antiviral

KW - combined antiretroviral therapy

KW - dual therapy

UR - https://publicatt.unicatt.it/handle/10807/68424

UR - https://www.scopus.com/inward/citedby.uri?partnerID=HzOxMe3b&scp=84930517019&origin=inward

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84930517019&origin=inward

U2 - 10.1093/jac/dkv037

DO - 10.1093/jac/dkv037

M3 - Article

SN - 0305-7453

VL - 70

SP - 1843

EP - 1849

JO - Journal of Antimicrobial Chemotherapy

JF - Journal of Antimicrobial Chemotherapy

IS - 6

ER -